Empaglifozin modifies the arterial stiffness in type-2 diabetic patients: a preliminary report.

Back

ESC Professional Premium Access

Empaglifozin modifies the arterial stiffness in type-2 diabetic patients: a preliminary report.

Session: Real-world evidence on the cardiovascular effects of therapies for diabetes

Topic: Antidiabetic Pharmacotherapy

Speaker: Doctor M. Feola (Mondovi, IT)

Event: ESC Congress 2024

Congress Presentation

Add to my library

About the speaker

Doctor Mauro Feola

Cardiology Department, Mondovi (Italy)

1 presentation

0 follower

8 more presentations in this session

Cardiometabolic outcomes in patients with overweight and obesity undergoing weight loss trials : a network meta-analysis

Speaker: Mr B. Tan (Singapore, SG)

The effect of metformin use on the risk of atrial fibrillation in patients with type 2 diabetes: data from the UK biobank

Speaker: Doctor T. Guo (Xi'an, CN)

The potential protective effect of dapagliflozin on the development of cardiotoxicity in cancer patients after one year of observation.

Speaker: Doctor S. Maragkoudakis (Chania, GR)

All cause mortality in people with type 2 diabetes using SGLT-2 inhibitors compared to DPP4 inhibitors using the danish registries

Speaker: Doctor P. Yazdanfard (Hilleroed, DK)

Identification and optimisation of a risk stratified cohort of patients with type 2 diabetes through the delivery of a enhanced pharmacist-led service

Speaker: Mr S. Mcbrien (Belfast, GB)

Access the full session

Real-world evidence on the cardiovascular effects of therapies for diabetes

Speakers: Doctor M. Feola, Mr B. Tan, Doctor T. Guo, Doctor S. Maragkoudakis, Doctor P. Yazdanfard...

Access

About the event

ESC Congress 2024

30 August - 2 September 2024

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources